Colony-stimulating factors: Beyond the effects on hematopoiesis

American Journal of Health-System Pharmacy

Volumn 59, Issue SUPPL. 2, 2002, Pages

  Stull, Dawn Marie ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Drug comparisons; Filgrastim; Mechanism of action; Neutropenia; Sargramostim

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; LEUKEMIA; MAJOR CLINICAL STUDY; MELANOMA; MULTICENTER STUDY; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TH2 CELL;

EID: 0036533724     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.suppl_2.s12     Document Type: Conference Paper

References (40)

1. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor
2. Dymanics of T lymphocyte responses: Intermediates, effectors, and memory cells
3. The potential role of GMCSF and G-CSF in infectious diseases
4. Recombinant human granulocyte-macrophage colony stimulating factor in patients with advanced malignancy: A phase 1b trial
5. The effect of recombinant human granulocyte macrophage colony stimulating factor on neutrophil activation in patients with refractory carcinoma
6. Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3
7. Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony stimulating factor, IFN gamma, and IL-3
8. A randomized placebo-controlled phase III study of granulocyte-macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
9. Incidence of infections in adult patients (>55 years) with acute myelogenous leukemia treated with yeast-derived GM-CSF (sargramostim): Results of a double-blind prospective study by the ECOG
10. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A southwest oncology group study (9031)
11. A randomized, double-blind placebo controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia
12. Recombinant granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid cancer
13. Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer
14. Granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjunct to autologous hematopoietic stem cell transplantation for lymphoma
15. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: A retrospective analysis
16. Phase III randomized, double blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation
17. Results of a randomized, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation
18. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies
19. Granulocyte colony stimulating factor after allogeneic bone marrow transplantation
20. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: A prospective, randomized trial
21. Mobilization of normal donors with G-CSF + GM-CSF is associated with improved yield of hematopoietic progenitors and increased numbers of activated dendritic cells
22. Mobilization of CD34+ cells, lymphoma cells, dendritic cells and NK-cells in non-Hodgkin's lymphoma patients primed with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF followed by G-CSF
23. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
24. A randomized study of G-CSF versus the combination of G-CSF/GM-CSF on mobilization of dendritic cells in peripheral stem cell grafts
25. Post-grafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants
26. Dendritic cells: A novel therapeutic modality
27. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
28. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony stimulating factor
29. Intradermal injection of granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells
30. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma
31. Therapy of advanced prostate cancer with granulocyte macrophage colony stimulating factor
32. Phase II trial of granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with advanced prostate cancer
33. Clinical and immunological effects of granulocyte-macrophage colony stimulating factor coadministered with interleukin 2: A phase IB study
34. GM-CSF can cause T-cell activation; results of sequential chemo-immunotherapy
35. A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF an innovative protocol for the treatment of metastatic melanoma
36. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF
37. Granulocyte-macrophage colony stimulating factor in metastatic renal cell carcinoma
38. Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma
39. Phase I trail of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive renal cell carcinoma
40. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer